Search

Displaying results 2461 - 2470 of 7540 in total
  1. Drug

    Ibandronate

    go.drugbank.com/drugs/DB00710
    ApprovedInvestigational

    [A203138] Ibandronate was granted FDA approval on 16 May 2003.[L13805] … Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].

  2. Drug

    Loracarbef

    go.drugbank.com/drugs/DB00447
    ApprovedWithdrawn

    Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.

  3. Drug

    Saxagliptin

    go.drugbank.com/drugs/DB06335
    ApprovedInvestigational

    FDA approved on July 31, 2009.

  4. Drug

    Medifoxamine

    go.drugbank.com/drugs/DB13219
    Approved

    Medifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity

  5. Drug

    Zolbetuximab

    go.drugbank.com/drugs/DB15118
    ApprovedInvestigational

    [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]

  6. Drug

    Carbenicillin

    go.drugbank.com/drugs/DB00578
    Approved

    It is susceptible to gastric juice and penicillinase and may damage platelet function.

    Synonyms: N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid
  7. Drug

    Rifapentine

    go.drugbank.com/drugs/DB01201
    ApprovedInvestigational

    Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.

  8. Drug

    Etelcalcetide

    go.drugbank.com/drugs/DB12865
    ApprovedInvestigational

    Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.

  9. Drug

    Solifenacin

    go.drugbank.com/drugs/DB01591
    ApprovedInvestigational

    [L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511] … Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.

  10. Drug

    Polihexanide

    go.drugbank.com/drugs/DB12277
    ApprovedInvestigational

    [L53003] It was initially approved in August of 2024, and is the first and only approved therapy to treat patients with _Acanthamoeba_ keratitis. [L53143] … [A1351,A273908] Polihexanide is approved in Europe under the name Akantior for the treatment of _Acanthamoeba_ keratitis, an ocular infection caused by the _Acanthamoeba_ parasite.